To date, R-Pharm has already brought more than 30 oncology drugs to market, with over 15 more molecules in the final stages of development and planned for registration within the next two years. The portfolio’s foundation consists of reproduced chemical and biological drugs. Among them are biosimilars of monoclonal antibodies, the likes of which have not yet appeared on the Russian market.
Work is also underway on innovative drugs. The group of companies includes a unit responsible for early-stage development, where biological molecules are created from scratch. A technological platform for developing monoclonal antibodies is already operational, the setup of a platform for creating bispecific antibodies is being finalized, and in 2026, R-Pharm will begin creating a platform for developing antibody-toxin conjugates. Six original anti-tumor molecules are currently in the early development stage.
“A new era in the company’s history will begin in 2026 — we have adopted an innovation development strategy. By expanding research capabilities to develop promising molecules and following global trends, we will contribute to saturating the market for anti-tumor therapy with advanced, effective drugs,” said Olga Filon, Director of Science and Research at R-Pharm, during the XXIX Russian Oncological Congress, which took place in Moscow with the participation of scientists, doctors, and pharmaceutical company representatives.
Another new direction for the company is the repurposing of already registered drugs, olokizumab and goflikicept, to combat immune system-related adverse events in CAR-T therapy. The drugs block the inflammatory molecules interleukin-6 and interleukin-1, respectively.
“CAR-T therapy is highly effective for certain oncohematological diseases, but there is a risk of life-threatening adverse events, such as CRS — cytokine release syndrome. If we can increase the safety of the therapy, we will be able to save more lives,” said Olga Filon.
A clinical trial of CAR-T therapy is currently being conducted in collaboration with the National Medical Research Center for Hematology, in which olokizumab is used to manage cytokine release syndrome.
